Cargando…
Quality of Life in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids: Baseline Disease Burden from Elaris UF-1 and UF-2
STUDY OBJECTIVE: Report baseline Uterine Fibroid Symptoms Quality of Life Questionnaire (UFS-QoL) data from Elaris UF-1 and UF-2 to characterize disease burden from heavy menstrual bleeding (HMB) associated with uterine fibroids (UF). DESIGN: Elaris UF-1 (NCT02654054) and UF-2 (NCT02691494) were ide...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572045/ http://dx.doi.org/10.1016/j.jmig.2020.08.177 |
_version_ | 1783597267849052160 |
---|---|
author | Gillispie, V. Al-Hendy, A. Kim, J.H. Wang, A. Kumar, M. Eichner, S. Xue, Z. Schlaff, W. |
author_facet | Gillispie, V. Al-Hendy, A. Kim, J.H. Wang, A. Kumar, M. Eichner, S. Xue, Z. Schlaff, W. |
author_sort | Gillispie, V. |
collection | PubMed |
description | STUDY OBJECTIVE: Report baseline Uterine Fibroid Symptoms Quality of Life Questionnaire (UFS-QoL) data from Elaris UF-1 and UF-2 to characterize disease burden from heavy menstrual bleeding (HMB) associated with uterine fibroids (UF). DESIGN: Elaris UF-1 (NCT02654054) and UF-2 (NCT02691494) were identical, phase 3, double-blind, randomized, placebo-controlled studies investigating safety and efficacy of elagolix alone or combined with hormonal add-back therapy for HMB associated with UF. SETTING: Outpatient in clinic/office. PATIENTS OR PARTICIPANTS: Premenopausal women (n=790) aged 18–51 years with diagnosed UF and HMB (menstrual blood loss [MBL] >80 mL/cycle for ≥2 menses). INTERVENTIONS: N/A MEASUREMENTS AND MAIN RESULTS: A modified UFS-QoL (4-week recall) was conducted before study drug administration. UFS-QoL is a self-administered, 37-item, disease-specific questionnaire that measures symptom severity and health-related QoL (HRQoL; calculated from 6 subscales and scored 0–100). Lower HRQoL scores indicate worse QoL. At baseline, mean (standard deviation [SD]) age was 42.4 (5.4) years, and MBL was 239.7 (158.7) mL. Baseline total HRQoL score was low, reflecting low QoL (mean [SD], 42.9 [23.2]). Mean (SD) scores were generally low across HRQoL domains (concern, 28.1 [24.6]; activities, 40.9 [27.0]; energy/mood, 47.4 [25.3]; control, 54.2 [28.3]; self-consciousness, 39.9 [30.7]; sexual function, 47.5 [35.4]). In each HRQoL domain, the questions most frequently answered ‘most’ or ‘all’ of the time were how often symptoms made patients: feel concerned about soiling underclothes (80%; concern), decrease the amount of time on exercise or other physical activities (59%; activities), feel tired or worn out (68%; energy/mood), feel less productive (50%; control), feel conscious about the size and appearance of their stomach (57%; self-consciousness), and avoid sexual relations (46%; sexual function). CONCLUSION: There was considerable baseline disease burden. Patients reported the greatest impacts to concern and self-consciousness. Common issues included concerns about soiling underclothes and feeling tired or worn out. |
format | Online Article Text |
id | pubmed-7572045 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Published by Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75720452020-10-20 Quality of Life in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids: Baseline Disease Burden from Elaris UF-1 and UF-2 Gillispie, V. Al-Hendy, A. Kim, J.H. Wang, A. Kumar, M. Eichner, S. Xue, Z. Schlaff, W. J Minim Invasive Gynecol Article STUDY OBJECTIVE: Report baseline Uterine Fibroid Symptoms Quality of Life Questionnaire (UFS-QoL) data from Elaris UF-1 and UF-2 to characterize disease burden from heavy menstrual bleeding (HMB) associated with uterine fibroids (UF). DESIGN: Elaris UF-1 (NCT02654054) and UF-2 (NCT02691494) were identical, phase 3, double-blind, randomized, placebo-controlled studies investigating safety and efficacy of elagolix alone or combined with hormonal add-back therapy for HMB associated with UF. SETTING: Outpatient in clinic/office. PATIENTS OR PARTICIPANTS: Premenopausal women (n=790) aged 18–51 years with diagnosed UF and HMB (menstrual blood loss [MBL] >80 mL/cycle for ≥2 menses). INTERVENTIONS: N/A MEASUREMENTS AND MAIN RESULTS: A modified UFS-QoL (4-week recall) was conducted before study drug administration. UFS-QoL is a self-administered, 37-item, disease-specific questionnaire that measures symptom severity and health-related QoL (HRQoL; calculated from 6 subscales and scored 0–100). Lower HRQoL scores indicate worse QoL. At baseline, mean (standard deviation [SD]) age was 42.4 (5.4) years, and MBL was 239.7 (158.7) mL. Baseline total HRQoL score was low, reflecting low QoL (mean [SD], 42.9 [23.2]). Mean (SD) scores were generally low across HRQoL domains (concern, 28.1 [24.6]; activities, 40.9 [27.0]; energy/mood, 47.4 [25.3]; control, 54.2 [28.3]; self-consciousness, 39.9 [30.7]; sexual function, 47.5 [35.4]). In each HRQoL domain, the questions most frequently answered ‘most’ or ‘all’ of the time were how often symptoms made patients: feel concerned about soiling underclothes (80%; concern), decrease the amount of time on exercise or other physical activities (59%; activities), feel tired or worn out (68%; energy/mood), feel less productive (50%; control), feel conscious about the size and appearance of their stomach (57%; self-consciousness), and avoid sexual relations (46%; sexual function). CONCLUSION: There was considerable baseline disease burden. Patients reported the greatest impacts to concern and self-consciousness. Common issues included concerns about soiling underclothes and feeling tired or worn out. Published by Elsevier Inc. 2020 2020-10-19 /pmc/articles/PMC7572045/ http://dx.doi.org/10.1016/j.jmig.2020.08.177 Text en Copyright © 2020 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Gillispie, V. Al-Hendy, A. Kim, J.H. Wang, A. Kumar, M. Eichner, S. Xue, Z. Schlaff, W. Quality of Life in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids: Baseline Disease Burden from Elaris UF-1 and UF-2 |
title | Quality of Life in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids: Baseline Disease Burden from Elaris UF-1 and UF-2 |
title_full | Quality of Life in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids: Baseline Disease Burden from Elaris UF-1 and UF-2 |
title_fullStr | Quality of Life in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids: Baseline Disease Burden from Elaris UF-1 and UF-2 |
title_full_unstemmed | Quality of Life in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids: Baseline Disease Burden from Elaris UF-1 and UF-2 |
title_short | Quality of Life in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids: Baseline Disease Burden from Elaris UF-1 and UF-2 |
title_sort | quality of life in women with heavy menstrual bleeding associated with uterine fibroids: baseline disease burden from elaris uf-1 and uf-2 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572045/ http://dx.doi.org/10.1016/j.jmig.2020.08.177 |
work_keys_str_mv | AT gillispiev qualityoflifeinwomenwithheavymenstrualbleedingassociatedwithuterinefibroidsbaselinediseaseburdenfromelarisuf1anduf2 AT alhendya qualityoflifeinwomenwithheavymenstrualbleedingassociatedwithuterinefibroidsbaselinediseaseburdenfromelarisuf1anduf2 AT kimjh qualityoflifeinwomenwithheavymenstrualbleedingassociatedwithuterinefibroidsbaselinediseaseburdenfromelarisuf1anduf2 AT wanga qualityoflifeinwomenwithheavymenstrualbleedingassociatedwithuterinefibroidsbaselinediseaseburdenfromelarisuf1anduf2 AT kumarm qualityoflifeinwomenwithheavymenstrualbleedingassociatedwithuterinefibroidsbaselinediseaseburdenfromelarisuf1anduf2 AT eichners qualityoflifeinwomenwithheavymenstrualbleedingassociatedwithuterinefibroidsbaselinediseaseburdenfromelarisuf1anduf2 AT xuez qualityoflifeinwomenwithheavymenstrualbleedingassociatedwithuterinefibroidsbaselinediseaseburdenfromelarisuf1anduf2 AT schlaffw qualityoflifeinwomenwithheavymenstrualbleedingassociatedwithuterinefibroidsbaselinediseaseburdenfromelarisuf1anduf2 |